Expression patterns of maspin and mutant p53 are associated with the development of gestational trophoblastic neoplasia

Sun,Pengming; Wu,Qibin; Ruan,Guanyu; Zheng,Xiu; Song,Yiyi; Zhun,Jianfan; Wu,Lixiang; Gotlieb,Walter   H.

doi:10.3892/ol.2016.5074

Expression patterns of maspin and mutant p53 are associated with the development of gestational trophoblastic neoplasia

Authors:
- Pengming Sun
- Qibin Wu
- Guanyu Ruan
- Xiu Zheng
- Yiyi Song
- Jianfan Zhun
- Lixiang Wu
- Walter H. Gotlieb
View Affiliations

Affiliations: Institute of Gynecologic Oncology, Fujian Maternity and Children Health Hospital, Teaching Hospital of Fujian Medical University, Fuzhou, Fujian 350001, P.R. China, Department of Obstetrics and Gynecology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian 350005, P.R. China, Department of Pathology, Fujian Maternity and Children Health Hospital, Teaching Hospital of Fujian Medical University, Fuzhou, Fujian 350001, P.R. China, Department of Gynecologic Oncology and Colposcopy, Jewish General Hospital, Mcgill University, Montreal, Quebec H3T1E2, Canada
Published online on: September 1, 2016 https://doi.org/10.3892/ol.2016.5074
Pages: 3135-3142
Copyright: © Sun et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Gestational trophoblastic disease (GTD) is a group of conditions that originate from the abnormal proliferation of trophoblastic cells. GTDs encompass hydatidiform moles (HMs) and gestational trophoblastic neoplasia (GTN). GTNs are a group of malignant diseases that require chemotherapy, or more aggressive treatment. There is a requirement for more tumor markers to predict the development of GTN from HMs. The current study evaluated the expression of maspin and tumor protein p53 (p53) in GTD, and their role in predicting the development of GTN. Expression of maspin and mutant p53 (m‑p53) was detected by immunohistochemistry in 48 normal first trimester placentas, matched for gestational age to 49 HMs that regressed, 39 malignant HMs and 11 invasive moles or choriocarcinomas. Spearman's rank correlation analysis and logistic regression were performed on the expression patterns of maspin and m‑p53, and on the clinical prognostic factors in GTD. Compared with normal placenta levels, the expression levels of maspin were decreased, whereas the expression levels of m‑p53 were increased in GTDs (P<0.05). The expression levels of maspin and m‑p53 in complete and partial HMs were not significantly different (P>0.05). In HMs, maspin expression was inversely correlated with serum β human chorionic gonadotropin, uterine size and diameter of theca‑lutein cysts; however, m‑p53 expression demonstrated a positive correlation with these factors (all P<0.05). Compared with the high‑risk metastatic group (FIGO score ≥7), the low‑risk group (FIGO score <7) exhibited a higher rate of positive maspin expression (P=0.041), and the frequency of positive m‑p53 expression was significantly higher in patients with an advanced FIGO stages (FIGO stage ≥III) compared with patients in early stages (FIGO stage ≤II; 87.9 vs. 58.8%; P=0.019). The combination of maspin negative expression with m‑p53 positive expression had an 84% specificity value, 76% positive predictive value and 70% negative predictive value for the development of GTN. In conclusion, maspin‑negative and m‑p53‑positive expression is associated with the development of GTN in HMs.

View Figures

View References

1	Savage P, Williams J, Wong SL, Short D, Casalboni S, Catalano K and Seckl M: The demographics of molar pregnancies in England and Wales from 2000–2009. J Reprod Med. 55:341–345. 2010.PubMed/NCBI
2	Grimes DA: Epidemiology of gestational trophoblastic disease. Am J Obstet Gynecol. 150:309–318. 1984. View Article : Google Scholar : PubMed/NCBI
3	Bracken MB, Brinton LA and Hayashi K: Epidemiology of hydatidiform mole and choriocarcinoma. Epidemiol Rev. 6:52–75. 1984.PubMed/NCBI
4	Bracken MB: Incidence and aetiology of hydatidiform mole: An epidemiological review. Br J Obstet Gynaecol. 94:1123–1135. 1987. View Article : Google Scholar : PubMed/NCBI
5	Shi YF, Li JQ, Zheng W, Chen XJ, Qiao YH, Hao M, Zhou CW, Hu YL, Wan GM, Sha YC and Zheng X: Survey of gestational trophoblastic disease incidence among 3.6 million pregnancies in China. Zhonghua Fu Chan Ke Za Zhi. 40:76–78. 2005.(In Chinese). PubMed/NCBI
6	Ngu SF and Chan KK: Management of Chemoresistant and quiescent gestational trophoblastic disease. Curr Obstet Gynecol Rep. 3:84–90. 2014. View Article : Google Scholar : PubMed/NCBI
7	Powles T, Savage PM, Stebbing J, Short D, Young A, Bower M, Pappin C, Schmid P and Seckl MJ: A comparison of patients with relapsed and chemo-refractory gestational trophoblastic neoplasia. Br J Cancer. 96:732–737. 2007. View Article : Google Scholar : PubMed/NCBI
8	Ie M Shih: Gestational trophoblastic neoplasia-pathogenesis and potential therapeutic targets. Lancet Oncol. 8:642–650. 2007. View Article : Google Scholar : PubMed/NCBI
9	Nguyen NM and Slim R: Genetics and epigenetics of recurrent Hydatidiform moles: Basic science and genetic counselling. Curr Obstet Gynecol Rep. 3:55–64. 2014. View Article : Google Scholar : PubMed/NCBI
10	Zou Z, Anisowicz A, Hendrix MJ, Thor A, Neveu M, Sheng S, Rafidi K, Seftor E and Sager R: Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells. Science. 263:526–529. 1994. View Article : Google Scholar : PubMed/NCBI
11	Khalkhali-Ellis Z: Maspin: The new frontier. Clin Cancer Res. 12:7279–7283. 2006. View Article : Google Scholar : PubMed/NCBI
12	Kaplun A, Dzinic S, Bernardo M and Sheng S: Tumor suppressor maspin as a rheostat in HDAC regulation to achieve the fine-tuning of epithelial homeostasis. Crit Rev Eukaryot Gene Expr. 22:249–258. 2012. View Article : Google Scholar : PubMed/NCBI
13	Bodenstine TM, Seftor RE, Khalkhali-Ellis Z, Seftor EA, Pemberton PA and Hendrix MJ: Maspin: Molecular mechanisms and therapeutic implications. Cancer Metastasis Rev. 31:529–551. 2012. View Article : Google Scholar : PubMed/NCBI
14	Choy B, Findeis-Hosey JJ, Li F, McMahon LA, Yang Q and Xu H: High frequency of coexpression of maspin with p63 and p53 in squamous cell carcinoma but not in adenocarcinoma of the lung. Int J Clin Exp Pathol. 6:2542–2547. 2013.PubMed/NCBI
15	Secord A Alvarez, Darcy KM, Hutson A, Huang Z, Lee PS, Jewell EL, Havrilesky LJ, Markman M, Muggia F and Murphy SK: The regulation of MASPIN expression in epithelial ovarian cancer: Association with p53 status, and MASPIN promoter methylation: A gynecologic oncology group study. Gynecol Oncol. 123:314–319. 2011. View Article : Google Scholar : PubMed/NCBI
16	Wang SE, Narasanna A, Whitell CW, Wu FY, Friedman DB and Arteaga CL: Convergence of p53 and transforming growth factor beta (TGFbeta) signaling on activating expression of the tumor suppressor gene maspin in mammary epithelial cells. J Biol Chem. 282:5661–5669. 2007. View Article : Google Scholar : PubMed/NCBI
17	Ngan HY, Bender H, Benedet JL, Jones H, Montruccoli GC and Pecorelli S: FIGO Committee on Gynecologic Oncology. Gestational trophoblastic neoplasia, FIGO 2000 staging and classification. Int J Gynaecol Obstet. 83(Suppl 1): S175–S177. 2003.
18	Chan HY, Siu MK, Zhang HJ, Wong ES, Ngan HY, Chan KY and Cheung AN: Activated Stat3 expression in gestational trophoblastic disease: Correlation with clinicopathological parameters and apoptotic indices. Histopathology. 53:139–146. 2008. View Article : Google Scholar : PubMed/NCBI
19	Zhang HJ, Xue WC, Siu MK, Liao XY, Ngan HY and Cheung AN: P63 expression in gestational trophoblastic disease: Correlation with proliferation and apoptotic dynamics. Int J Gynecol Pathol. 28:172–178. 2009. View Article : Google Scholar : PubMed/NCBI
20	Chen RJ, Chu CT, Huang SC, Chow SN and Hsieh CY: Telomerase activity in gestational trophoblastic disease and placental tissue from early and late human pregnancies. Hum Reprod. 17:463–468. 2002. View Article : Google Scholar : PubMed/NCBI
21	Chiu PM, Ngan YS, Khoo US and Cheung AN: Apoptotic activity in gestational trophoblastic disease correlates with clinical outcome: Assessment by the caspase-related M30 CytoDeath antibody. Histopathology. 38:243–249. 2001. View Article : Google Scholar : PubMed/NCBI
22	Rumer KK, Post MD, Larivee RS, Zink M, Uyenishi J, Kramer A, Teoh D, Bogart K and Winn VD: Siglec-6 is expressed in gestational trophoblastic disease and affects proliferation, apoptosis and invasion. Endocr Relat Cancer. 19:827–840. 2012. View Article : Google Scholar : PubMed/NCBI
23	Li HW, Leung SW, Cheung AN, Yu MM, Chan LK and Wong YF: Expression of maspin in gestational trophoblastic disease. Gynecol Oncol. 101:76–81. 2006. View Article : Google Scholar : PubMed/NCBI
24	Cheung AN, Shen DH, Khoo US, Chiu MP, Tin VP, Chung LP and Ngan HY: Immunohistochemical and mutational analysis of p53 tumor suppressor gene in gestational trophoblastic disease: Correlation with mdm2, proliferation index, and clinicopathologic parameters. Int J Gynecol Cancer. 9:123–130. 1999. View Article : Google Scholar : PubMed/NCBI
25	Marioni G, Zanoletti E, Stritoni P, Lionello M, Giacomelli L, Gianatti A, Cattaneo L, Blandamura S, Mazzoni A and Martini A: Expression of the tumour-suppressor maspin in temporal bone carcinoma. Histopathology. 63:242–249. 2013. View Article : Google Scholar : PubMed/NCBI
26	Bai SS, Pang YC and LM T: HZ. The effect of Maspin on malignant transformation of hydatidiform mole. Chin J Family Planning & Gynecotokology. 03:10–13. 2011.(In Chinese).
27	Seftor RE, Seftor EA, Sheng S, Pemberton PA, Sager R and Hendrix MJ: Maspin suppresses the invasive phenotype of human breast carcinoma. Cancer Res. 58:5681–5685. 1998.PubMed/NCBI
28	Zhang M, Volpert O, Shi YH and Bouck N: Maspin is an angiogenesis inhibitor. Nat Med. 6:196–199. 2000. View Article : Google Scholar : PubMed/NCBI
29	Lee DY, Park CS, Kim HS, Kim JY, Kim YC and Lee S: Maspin and p53 protein expression in gastric adenocarcinoma and its clinical applications. Appl Immunohistochem Mol Morphol. 16:13–18. 2008.PubMed/NCBI
30	Sedic M, Poznic M, Gehrig P, Scott M, Schlapbach R, Hranjec M, Karminski-Zamola G, Pavelic K and Pavelic S Kraljevic: Differential antiproliferative mechanisms of novel derivative of benzimidazo[1,2-alpha]quinoline in colon cancer cells depending on their p53 status. Mol Cancer Ther. 7:2121–2132. 2008. View Article : Google Scholar : PubMed/NCBI